Treatment for polycythemia vera (PV) follows a layered strategy built around one central goal: preventing blood clots. Phlebotomy, the controlled removal of blood, is the backbone of therapy for nearly every patient, but it is rarely the whole picture. Low-dose aspirin, cytoreductive drugs like hydroxyurea and interferon, and targeted JAK inhibitors each play distinct roles depending on a person’s risk profile and how their disease responds over time. Getting the right combination matters because PV, if poorly controlled, carries a serious risk of stroke, heart attack, and other vascular events.
What Makes PV Dangerous
PV is driven by a mutation in the JAK2 gene, present in about 97% of cases, that causes the bone marrow to overproduce red blood cells.1memo – Magazine of European Medical Oncology. JAK2 mutations in polycythemia vera: from molecular origins to inflammatory pathways and clinical implications The excess red cells thicken the blood, raising its viscosity. That thicker blood moves more sluggishly through vessels and is far more prone to clotting. Thrombotic complications can hit both arteries and veins, showing up as stroke, heart attack, deep vein thrombosis, or pulmonary embolism.2PubMed. Hyperviscosity in polycythemia vera and other red cell abnormalities Several other factors pile on top of the viscosity problem, including platelet activation, white blood cell activation, and endothelial damage, making the thrombotic risk in PV more complex than a simple matter of “too many red cells.”
It is worth noting that high hematocrit alone does not automatically cause clots. Most other forms of erythrocytosis, where the red cell count rises for different reasons, do not carry the same thrombotic burden PV does.3PubMed Central. Re-evaluation of hematocrit as a determinant of thrombotic risk in erythrocytosis The JAK2 mutation itself appears to contribute to clotting risk through inflammatory pathways and abnormal cell signaling beyond just boosting red cell numbers. That is why treatment for PV specifically targets both the hematocrit and the underlying disease biology, rather than just draining off blood.
How Doctors Decide Who Needs What
Before choosing a treatment plan, doctors sort patients into two risk categories based on their chance of developing a major blood clot. The system is straightforward: you are considered high-risk if you are older than 60 or have a history of thrombosis. If neither of those applies, you are low-risk.4PubMed. Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management This two-tier system has been the convention for years and guides the intensity of treatment.
Low-risk patients typically receive phlebotomy plus low-dose aspirin, and that may be enough to keep them safe for years. High-risk patients get those same treatments plus a cytoreductive drug, a medication that reduces the bone marrow’s output of blood cells. The distinction matters because cytoreductive therapy carries its own side effects, so it is reserved for people whose clot risk justifies the trade-off.
The Hematocrit Target That Changed Practice
For a long time, the exact hematocrit level to aim for was debated. A landmark randomized trial published in the New England Journal of Medicine settled the question. The CYTO-PV study compared a strict target of below 45% against a more lenient target of 45% to 50%. After roughly two and a half years of follow-up, major cardiovascular events or deaths from cardiovascular causes occurred in about 2.7% of the group kept below 45%, compared with 9.8% of the group allowed to stay higher. The risk was nearly four times greater in the higher-hematocrit group.5PubMed. Cardiovascular events and intensity of treatment in polycythemia vera
That result made a hematocrit below 45% the universal standard of care. Every subsequent treatment decision, whether phlebotomy frequency, drug choice, or dose adjustment, is anchored to hitting and maintaining that number.
Phlebotomy as the Foundation
Phlebotomy is conceptually simple: remove blood, reduce red cell mass, lower hematocrit. A typical session takes about 350 to 500 milliliters of blood, similar in volume to a standard blood donation. Sessions are repeated every few days or every few weeks until the hematocrit drops below 45%, then spaced further apart for maintenance. One study using a fixed-volume protocol of 350 mL every three days found that mean hematocrit dropped from roughly 57% at baseline to about 46% over the treatment course, with significant symptom improvement and few adverse events.6PubMed. Revisiting the impact of serial therapeutic phlebotomy in polycythaemia on laboratory and clinical parameters using a fixed interval and fixed volume protocol
Reaching the target usually takes multiple sessions. One analysis found that achieving a hematocrit below 45% required an average of six phlebotomies.7The Korean Journal of Blood Transfusion. Assessment of Effects of Phlebotomy in Patients with Polycythemia Vera and Secondary Polycythemia The frequency of maintenance phlebotomy varies widely from person to person. Some patients need blood drawn every month or two; others go several months between sessions. A doctor adjusts the schedule based on how quickly the hematocrit creeps back up.
The Iron Deficiency Trade-Off
There is a catch with ongoing phlebotomy that does not get enough attention. Every unit of blood removed takes iron with it. Over time, repeated phlebotomy depletes iron stores, and many PV patients already have low iron at diagnosis because the marrow is consuming it so rapidly to churn out red cells.8PubMed. Iron deficiency and phlebotomy in patients with polycythemia vera The resulting iron deficiency can cause fatigue, brain fog, and poor concentration that can be just as debilitating as the disease symptoms themselves.
The tricky part is that giving iron supplements to correct this deficiency can push the hematocrit right back up, undoing the point of phlebotomy. So patients and doctors are often stuck managing a frustrating balancing act. This unresolved tension is one of the main reasons newer, non-phlebotomy approaches have generated so much interest.
Low-Dose Aspirin
Almost every PV patient, regardless of risk category, takes low-dose aspirin daily. Aspirin reduces platelet stickiness and is currently a standard recommendation for this disease.9PubMed Central. Platelet thromboxane inhibition by low-dose aspirin in polycythemia vera: Ex vivo and in vivo measurements and in silico simulation The evidence behind this comes from the ECLAP trial, which enrolled hundreds of PV patients and compared aspirin to placebo. The aspirin group saw a roughly 60% reduction in the combined risk of heart attack, stroke, major venous thrombosis, pulmonary embolism, and cardiovascular death, without a significant increase in major bleeding.10PubMed. Efficacy and safety of low-dose aspirin in polycythemia vera
There is some emerging discussion about whether certain patients with very high platelet counts benefit from twice-daily aspirin rather than once-daily, because aspirin’s antiplatelet effect may wear off faster in PV. But for most patients, once-daily low-dose aspirin remains the standard.
Hydroxyurea as First-Line Cytoreduction
When phlebotomy and aspirin are not enough to keep the disease controlled, or when a patient falls into the high-risk category, the most commonly prescribed first-line cytoreductive drug is hydroxyurea. It works by broadly suppressing the bone marrow’s activity, reducing the production of red cells, white cells, and platelets. It is taken as a daily oral pill, and its dose is adjusted based on blood counts.
Hydroxyurea is effective and well studied, but it is not without problems. Some patients cannot tolerate it because of side effects like mouth sores, skin changes, or gastrointestinal symptoms. Others develop resistance over time, meaning their disease stops responding despite adequate dosing. When either of those things happens, treatment needs to shift to a second-line agent.11PubMed Central. Ruxolitinib versus standard therapy for the treatment of polycythemia vera How often this happens varies, but it is a well-recognized limitation of the drug.
Interferons and the Possibility of Deeper Responses
Interferon-based therapy has undergone something of a renaissance in PV treatment. Older forms of interferon were effective but hard to tolerate because of flu-like side effects and the need for frequent injections. The newer pegylated formulation, ropeginterferon alfa-2b, is injected only every two weeks and produces far fewer side effects, making long-term treatment practical.
What sets interferon apart from hydroxyurea is its ability to reduce the burden of the disease at a molecular level. Over five years of treatment, ropeginterferon drove the median JAK2 mutation burden down from about 37% at baseline to 8.5%. In the control group, the mutation burden initially dipped but then rebounded to above 44% by the same time point. About half of ropeginterferon-treated patients achieved a mutation burden below 10%, and roughly one in five got it below 1%, compared to just one patient in the control arm.12PubMed Central. Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b
These deep molecular responses suggest that interferon may be doing more than controlling symptoms; it may be gradually exhausting the mutant clone that drives the disease. Whether this translates into longer survival or reduced transformation to more aggressive blood cancers is still being studied, but the data have made many hematologists view interferon as a genuine contender for first-line cytoreduction, especially in younger patients who face decades of treatment.
Ruxolitinib for Hydroxyurea Failures
Ruxolitinib is a targeted drug that blocks the JAK1 and JAK2 enzymes, directly interfering with the signaling pathway that the PV-driving mutation hijacks. It is approved for PV patients who have had an inadequate response to or cannot tolerate hydroxyurea. The RESPONSE trial demonstrated that ruxolitinib was superior to the best available alternative therapy for hematocrit control, spleen size reduction, and symptom improvement in these patients.11PubMed Central. Ruxolitinib versus standard therapy for the treatment of polycythemia vera At 32 weeks, about 60% of patients on ruxolitinib achieved hematocrit control compared with roughly 19% on other therapies, and the probability of maintaining that response for 80 weeks or more was about 89%.13PubMed Central. Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial
A more recent randomized trial, RESPONSE-2 and MAJIC-PV, reinforced these findings. In the MAJIC-PV trial, about 43% of patients on ruxolitinib achieved a complete response compared to 26% on other therapy, and the duration of response was substantially longer. Patients who achieved a complete response within a year also had better event-free survival, meaning fewer major clots, hemorrhages, or disease transformations.14PubMed Central. Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial
Ruxolitinib has its own downsides. It can increase susceptibility to infections, particularly herpes zoster, and may cause weight gain. It does not produce the deep molecular responses that interferon does. But for patients whose quality of life is significantly impaired by symptoms like itching, night sweats, or an enlarged spleen, it can be transformative.
Aquagenic Pruritus and Other Quality-of-Life Burdens
One of the most distinctive and maddening symptoms of PV is aquagenic pruritus: intense itching triggered by contact with water, typically after a bath or shower. A large survey of 441 PV patients found that this itching seriously affects quality of life, yet only about a quarter of affected patients received any specific treatment for it. Antihistamines helped roughly half of those who tried them, and phlebotomy or cytoreductive therapy resolved symptoms in fewer than 6% of cases.15PubMed. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients Ruxolitinib has shown particular effectiveness against this symptom, and its approval gave many patients their first real relief from itching that had resisted everything else.
Beyond pruritus, PV produces a broader symptom burden that includes fatigue, headaches, difficulty concentrating, night sweats, and bone pain. A validated symptom scoring tool, the MPN Symptom Assessment Form, is now used in both clinical practice and research trials to track how patients actually feel, rather than relying solely on blood counts.16PubMed Central. Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs This matters because a hematocrit of 44% looks great on paper, but if the patient can barely function from fatigue or itching, the treatment picture is incomplete.
Rusfertide and the Promise of Chemical Phlebotomy
One of the most interesting drugs in late-stage development for PV is rusfertide, a hepcidin mimetic. Hepcidin is a natural hormone that controls how much iron the body absorbs and releases from storage. By mimicking hepcidin, rusfertide restricts the iron supply available for red cell production, achieving what has been described as a “chemical phlebotomy,” lowering the hematocrit without physically removing blood.17PubMed Central. Hepcidin mimetics in polycythemia vera: resolving the irony of iron deficiency and erythrocytosis
Phase 2 trial results have been striking. Patients who needed an average of about 4.6 phlebotomies in the 28 weeks before enrollment needed only 0.4 after starting rusfertide. The drug maintained hematocrit consistently below 45%, essentially eliminating the need for phlebotomy. It also normalized ferritin levels and corrected iron deficiency, directly addressing the major quality-of-life downside of conventional phlebotomy.18Journal of Clinical Oncology. Rusfertide (PTG-300) treatment in phlebotomy-dependent polycythemia vera patients A global phase 3 trial is underway. If it confirms these results, rusfertide would be the first non-cytoreductive drug that controls hematocrit without the needle sticks and iron depletion that define current standard care.
Older and Less Common Drug Options
A few other cytoreductive agents still appear in clinical practice, mostly for patients who have failed or cannot take the main options. Busulfan, an older alkylating agent, has been used for decades and can produce durable responses. In one study of patients who had failed hydroxyurea, busulfan achieved a complete response in about 83% at a low daily dose.19PubMed. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea However, there has been longstanding concern about a risk of leukemic transformation with busulfan. Some researchers argue these concerns have been overstated, noting that transformation events in studies tended to occur in patients who already carried additional high-risk mutations.20Blood. Busulfan Induces Hematologic and Molecular Responses in Polycythemia Vera (PV) Refractory to Multiple Drugs Still, most guidelines reserve it primarily for elderly patients with limited alternatives.
Anagrelide is another drug sometimes used when the dominant problem is a very high platelet count rather than red cell excess. It selectively lowers platelets without affecting red cells much. But it carries a risk of cardiac side effects, including a form of cardiomyopathy that has been linked to the drug in case reports. In several documented cases, patients developed heart failure temporally associated with anagrelide use, and while most improved after stopping the drug, recovery was not always complete.21Blood. Anagrelide-Associated Cardiomyopathy in Polycythemia Vera and Essential Thrombocythemia Because of this cardiac risk, anagrelide is not a routine choice for PV and is used cautiously in specific situations.
Treatment During Pregnancy
Pregnancy in someone with PV requires special handling because the usual first-line drug, hydroxyurea, is contraindicated due to the risk of birth defects. Instead, pregnant patients rely on serial phlebotomy to keep hematocrit in range, daily low-dose aspirin, and low-molecular-weight heparin if there is an additional reason to worry about clotting. If cytoreduction is necessary, interferon alpha is the preferred option because it does not cross the placenta in significant amounts and has the most reassuring safety profile available during pregnancy.22Clinical and Experimental Obstetrics & Gynecology. Polycythemia Vera in Pregnancy: A Descriptive Review of the Literature Ruxolitinib lacks sufficient safety data in pregnancy and is generally avoided.
Disease Transformation and Why Long-Term Monitoring Matters
PV is a chronic condition that most people live with for many years, but it is not static. Over time, a fraction of patients will see their disease evolve into myelofibrosis, where the bone marrow becomes scarred and can no longer produce blood cells normally, or rarely into acute leukemia. Certain additional gene mutations beyond JAK2, particularly in genes like ASXL1, SRSF2, and IDH2, have been associated with worse survival and a higher chance of these transformations.23PubMed. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management Advanced age, elevated white cell counts, and a history of clotting events also raise the risk.
This means that managing PV is not a set-it-and-forget-it situation. Regular blood counts, periodic bone marrow assessments in some cases, and attention to emerging symptoms like a rapidly enlarging spleen, worsening fatigue, or unexplained fevers are all part of long-term care. When molecular testing reveals high-risk mutations, the threshold for starting or intensifying cytoreductive therapy may shift. Ongoing research into whether early aggressive treatment with drugs like interferon can reduce transformation risk may eventually reshape how doctors approach the disease from diagnosis onward.
Confirming the Diagnosis in the First Place
Before any of these treatments come into play, confirming that you actually have PV, rather than another cause of a high red cell count, is critical. A high hematocrit on routine bloodwork could be PV, but it could also be secondary polycythemia from chronic lung disease, sleep apnea, or living at high altitude, among other causes. The key differentiator is the serum erythropoietin level: in PV, it is characteristically low, because the bone marrow is producing red cells autonomously rather than in response to the body’s normal signaling hormone. A low erythropoietin level prompts testing for JAK2 mutations, which clinches the diagnosis in the vast majority of cases.24PubMed Central. Investigation and management of erythrocytosis Getting this distinction right matters enormously, because secondary polycythemia is treated by addressing its underlying cause, not with cytoreductive drugs or indefinite phlebotomy programs.